New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - zoledronic acid monohydrate 4.3mg equivalent to zoledronic acid 4 mg - concentrate for infusion - 4 mg/5ml - active: zoledronic acid monohydrate 4.3mg equivalent to zoledronic acid 4 mg excipient: mannitol sodium citrate dihydrate water for injection - prevention of skeletal-related events (pathological fracture, spinal cord compression, radiation to bone or surgery to bone) in patients with advanced malignancies involving bone

Philippines - English - FDA (Food And Drug Administration)

na - na - na

Philippines - English - FDA (Food And Drug Administration)

n/a; distributor: n/a - na - na - na

Philippines - English - FDA (Food And Drug Administration)

n/a; distributor: n/a - na - na - na

Philippines - English - FDA (Food And Drug Administration)

n/a; distributor: n/a - na - na - na

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol absolute; citric acid; polysorbate 80 - breast cancer,metastatic breast cancer,dotax is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,dotax in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,dotax in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,dotax in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by dotax in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,dotax in combination with carboplatin and trastuzuma

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid; ethanol absolute - breast cancer,metastatic breast cancer,dotax is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,dotax in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,dotax in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,dotax in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by dotax in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,dotax in combination with carboplatin and trastuzuma

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol absolute; polysorbate 80; citric acid - breast cancer,metastatic breast cancer,docetere is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetere in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetere in combination with carbopla

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel-rz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-rz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-rz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-rz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-rz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetaxel-rz in c

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; polysorbate 80; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel-drla is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-drla in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-drla in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-drla in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-drla in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetax